Cas:116380-66-6 cholic-2,2,4,4-d4 acid manufacturer & supplier

Chemical Name:cholic-2,2,4,4-d4 acid

CAS.NO:116380-66-6

Synonyms:(3α,5β,7α,12α)-3,7,12-Trihydroxy(2,2,4,4-H)cholan-24-oic acid;Cholan-24-oic-2,2,4,4-d acid, 3,7,12-trihydroxy-, (3α,5β,7α,12α)-;2,2,4,4-2H cholic acid;2,2,4,4,7,7,9,9-Octamethyl-3,8-dioxa-2,4,7,9-tetrasila-decan

Molecular Formula:C₂₄H₃₆D₄O₅

Molecular Weight:412.596

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:583.9±50.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.558

PSA:97.99000

Exact Mass:412.312683

LogP:2.62

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (3α,5β,7α,12α)-3,7,12-Trihydroxy(2,2,4,4-H)cholan-24-oic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,2,4,4,7,7,9,9-Octamethyl-3,8-dioxa-2,4,7,9-tetrasila-decan physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,2,4,4-2H cholic acid Use and application,2,2,4,4,7,7,9,9-Octamethyl-3,8-dioxa-2,4,7,9-tetrasila-decan technical grade,usp/ep/jp grade.

Related News: After speaking to iRhythm on Tuesday, J.P. Morgan analysts wrote we shouldn’t expect an update on reimbursement before the release of the Physician Fee Schedule proposed rule in July/August. (Z)-1,2-diphenyl-1-methylsulphonylethylene manufacturers IBI321 was discovered through a collaboration between Innovent and Eli Lilly and Company and has been developed in China by Innovent. The IND for IBI321 has been approved by the NMPA in China, and clinical trials in China are actively being conducted. 1,1′:3′,1′:2′,1”:3”,1”-Quinquephenyl, 4′,5′-bis[1,1′-biphenyl]-3-yl- suppliers TULIP-2 assessed the effect of anifrolumab in reducing disease activity as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale. In TULIP-1, 457 eligible patients were randomised (1:2:2) and received a fixed-dose intravenous infusion of 150mg anifrolumab, 300mg anifrolumab or placebo every four weeks, 2-(4-((4-(benzo[d][1,3]dioxol-5-yl)-2-hydroxy-2-(4-methoxyphenyl)-5-oxo-2,5-dihydrofuran-3-yl)methyl)phenyl)acetic acid vendor & factory.